{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:40:47Z","timestamp":1793936447373,"version":"4.8.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RO1NS139383"],"award-info":[{"award-number":["RO1NS139383"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.tjpad.2025.100394","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T16:50:09Z","timestamp":1760806209000},"page":"100394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease"],"prefix":"10.1016","volume":"13","author":[{"given":"Michael H","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-0264","authenticated-orcid":false,"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-6408","authenticated-orcid":false,"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everard","family":"Vijverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-1893","authenticated-orcid":false,"given":"Marc","family":"Ditmarsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Kling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1672-0760","authenticated-orcid":false,"given":"Danielle","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John JP","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.tjpad.2025.100394_bib0001","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.mp.4001854","article-title":"Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease","volume":"11","author":"Martins","year":"2006","journal-title":"Mol Psychiatry"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100394_bib0002","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrn2233","article-title":"A neuroscientist's guide to lipidomics","volume":"8","author":"Piomelli","year":"2007","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100394_bib0003","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1471-4159.2010.07017.x","article-title":"Cholesterol asymmetry in synaptic plasma membranes","volume":"116","author":"Wood","year":"2011","journal-title":"J Neurochem"},{"key":"10.1016\/j.tjpad.2025.100394_bib0004","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","article-title":"Apolipoprotein E: far more than a lipid transport protein","volume":"1","author":"Mahley","year":"2000","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100394_bib0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(10)70325-2","article-title":"Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders","volume":"10","author":"Verghese","year":"2011","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100394_bib0006","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100394_bib0007","first-page":"739","article-title":"ApoE4-induced cholesterol dysregulation and its brain cell type-specific implications in the pathogenesis of Alzheimer\u2019s disease","volume":"42","author":"Jeong","year":"2019","journal-title":"Mol Cells"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100394_bib0008","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.neuron.2022.03.004","article-title":"ApoE Cascade hypothesis in the pathogenesis of Alzheimer's disease and related dementias","volume":"115","author":"Martens","year":"2022","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100394_bib0009","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ije\/dyt034","article-title":"Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals","volume":"42","author":"Khan","year":"2013","journal-title":"Int J Epidemiol"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100394_bib0010","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0022-2275(20)36957-1","article-title":"Plasma cholesteryl ester transfer protein","volume":"34","author":"Tall","year":"1993","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100394_bib0011","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-023-00671-y","article-title":"Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia","volume":"18","author":"Poliakova","year":"2023","journal-title":"Mol Neurodegeneration"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100394_bib0012","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1194\/jlr.M300046-JLR200","article-title":"Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer\u2019s disease","volume":"44","author":"Vuletic","year":"2003","journal-title":"J Lip Research"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100394_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100260","article-title":"The cholesteryl ester transfer protein (CETP) raises cholesterol levels in the brain","volume":"63","author":"Oestereich","year":"2022","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100394_bib0014","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1212\/01.wnl.0000249116.50854.65","article-title":"A genotype of exceptional longevity is associated with preservation of cognitive function","volume":"67","author":"Barzilai","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100394_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jama.2009.1988","article-title":"Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia","volume":"303","author":"Sanders","year":"2010","journal-title":"JAMA"},{"issue":"200","key":"10.1016\/j.tjpad.2025.100394_bib0016","first-page":"e7","article-title":"Cholesteryl ester transfer protein genotype modifies the effect of apolipoprotein \u03b54 on memory decline in older adults","volume":"41","author":"Sundermann","year":"2016","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100394_bib0017","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.neurobiolaging.2014.08.022","article-title":"Population-based analysis of cholesteryl ester transfer protein identifies association between I405V and cognitive decline: the Cache County Study","volume":"36","author":"Lythgoe","year":"2015","journal-title":"Neurobiol Aging"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100394_bib0018","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00415-005-0945-2","article-title":"Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE epsilon4 allele","volume":"253","author":"Rodr\u00edguez","year":"2006","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100394_bib0019","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13195-024-01594-6","article-title":"Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis","volume":"16","author":"Schmidt","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100394_bib0020","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100394_bib0021","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","article-title":"Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers","volume":"80","author":"Mattsson-Carlgren","year":"2023","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100394_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70565","article-title":"Cognitive impairment and p-tau217 are higher in a vascular patient cohort","volume":"21","author":"French","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100394_bib0023","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100394_bib0024","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","article-title":"Obicetrapib: reversing the Tide of CETP Inhibitor Disappointments","volume":"26","author":"Kastelein","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.tjpad.2025.100394_bib0025","unstructured":"NewAmsterdam Pharma. Data on file. Proof-of-concept, open-label study in patients with early Alzheimer's disease. ClinicalTrials.gov Identifier 2023;NCT05161715."},{"issue":"3","key":"10.1016\/j.tjpad.2025.100394_bib0026","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of plasma phosphorylated tau 217 immunoassay for Alzheimer\u2019s disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100394_bib0027","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100394_bib0028","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ahj.2024.05.002","article-title":"Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN","volume":"274","author":"Nicholls","year":"2024","journal-title":"Am J Heart J"},{"issue":"9984","key":"10.1016\/j.tjpad.2025.100394_bib0029","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100394_bib0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2017.09.006","article-title":"Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial","volume":"14","author":"Rosenberg","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100394_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.12923","article-title":"Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: the US POINTER Randomized Clinical Trial","author":"Baker","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100394_bib0032","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100394_bib0033","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease","volume":"74","author":"Feldman","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100394_bib0034","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","article-title":"Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function","volume":"80","author":"Rosoff","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100394_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100394_bib0036","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100394_bib0037","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100394_bib0038","article-title":"Advances in developing novel therapeutic strategies for Alzheimer\u2019s disease","volume":"64","author":"Cao","year":"2018","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.tjpad.2025.100394_bib0039","first-page":"69","article-title":"Pathophysiologic relationship between Alzheimer\u2019s disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis","volume":"7","author":"Santos","year":"2017","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.tjpad.2025.100394_bib0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2796.2006.01687.x","article-title":"Cardiovascular disease and Alzheimer\u2019s disease: common links","volume":"260","author":"Stampfer","year":"2006","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100394_bib0041","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1179\/016164106X130515","article-title":"Interventions for heart disease and their effects on Alzheimer\u2019s disease","volume":"28","author":"Wolozin","year":"2006","journal-title":"Neurol Research"},{"issue":"28","key":"10.1016\/j.tjpad.2025.100394_bib0042","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehad293","article-title":"Combining genetic variants and cardiovascular risk factors can facilitate identification of high-risk individuals for targeted prevention of dementia","volume":"44","author":"Rasmussen","year":"2023","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100394_bib0043","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"7399","key":"10.1016\/j.tjpad.2025.100394_bib0044","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature11087","article-title":"Apolipoprotein E controls cerebrovascular integrity via cyclophilin A","volume":"485","author":"Bell","year":"2012","journal-title":"Nature"},{"issue":"7806","key":"10.1016\/j.tjpad.2025.100394_bib0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tjpad.2025.100394_bib0046","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.29595","article-title":"Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels","volume":"6","author":"Robert","year":"2017","journal-title":"Elife"},{"issue":"357","key":"10.1016\/j.tjpad.2025.100394_bib0047","doi-asserted-by":"crossref","first-page":"j1648","DOI":"10.1136\/bmj.j1648","article-title":"Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: mendelian randomisation study","volume":"24","author":"Benn","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.tjpad.2025.100394_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119560","article-title":"Obicetrapib significantly increases plasma and high-density lipoprotein (HDL) levels of antioxidants","volume":"407","author":"Niesor","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tjpad.2025.100394_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119512","article-title":"Low-dose obicetrapib significantly increases concentrations of lipophilic antioxidants, apoE, and S1P in hdl subfractions","volume":"407","author":"Niesor","year":"2025","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100394_bib0050","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100394_bib0051","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/jnc.15170","article-title":"High-density lipoprotein-related cholesterol metabolism in Alzheimer's disease","volume":"159","author":"Pedrini","year":"2021","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100394_bib0052","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3233\/JAD-2008-13103","article-title":"Nutritional biomarkers in Alzheimer\u2019s disease: the association between carotenoids, n-3 fatty acids, and dementia severity","volume":"13","author":"Wang","year":"2008","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100394_bib0053","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1194\/jlr.R400004-JLR200","article-title":"Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature anima","volume":"45","author":"Dietschy","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.tjpad.2025.100394_bib0054","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesteryl ester transfer protein inhibition by TA-8995 in patients with mild dyslipidemia (TULIP): a randomized, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100394_bib0055","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1471-4159.2004.02373.x","article-title":"Uptake and transport of high-density lipoprotein (HDL) and HDL-associated \u03b1-tocopherol by an in vitro blood-brain barrier model","volume":"89","author":"Balazs","year":"2004","journal-title":"J Neurochem"},{"issue":"24","key":"10.1016\/j.tjpad.2025.100394_bib0056","doi-asserted-by":"crossref","first-page":"26616","DOI":"10.1021\/acsomega.4c03353","article-title":"Lutein from chicken eggs prevent amyloid \u03b2-peptide aggregation in vitro and amyloid \u03b2-induced inflammation in human macrophages (THP-1)","volume":"9","author":"Matsui","year":"2024","journal-title":"ACS Omega"},{"issue":"47","key":"10.1016\/j.tjpad.2025.100394_bib0057","doi-asserted-by":"crossref","first-page":"36958","DOI":"10.1074\/jbc.M110.127829","article-title":"Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease","volume":"285","author":"Lewis","year":"2010","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100394_bib0058","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.14283\/jpad.2024.155","article-title":"Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform","volume":"5","author":"Zhang","year":"2024","journal-title":"J Prev Alz Dis"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100394_bib0059","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/biomedicines12081836","article-title":"P-tau217 as a reliable blood-based marker of Alzheimer\u2019s disease","volume":"13","author":"Lai","year":"2024","journal-title":"Biomedicines"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072500336X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072500336X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T03:19:54Z","timestamp":1764559194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S227458072500336X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S227458072500336X"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100394","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100394"}}